A Phase 3 interventional study of clarithromycin extended release (ER) and azithromycin SR in Pneumonia, sponsored by Pfizer. Completed at 72 sites in 7 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2008-03-26.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing azithromycin in Pneumonia — 1 open to participants now, 2 under way, 1 of them phase 3. Azithromycin · Pneumonia.
Among the 13 studies testing azithromycin in Pneumonia, this one is the 5th largest by enrollment, is one of 4 that started in 2003, is one of 5 in phase 3, and was the 6th registered.
1,568 studies on the registry are indexed under Pneumonia; 267 are open to participants now.
Browse Pneumonia studies →1 of the 13 studies testing azithromycin in Pneumonia is open now, in 12 countries. Recruiting first, the newest first:
University of Oxford · Sites in Belgium, Estonia, France and 13 more countries
Ages 0+
By country, each count listing its studies:
Azithromycin: first FDA approval 1991 (ZITHROMAX). What it is approved for, and how studies give it, is on its page →
Of the 158 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 41 take children under 18; 24 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 6 · Phase 4 6
First in 2003; this study’s year is marked. 4 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 504 is above the median of 128 across 977 interventional studies indexed under Pneumonia.
Median enrollment 151 across the 13 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 13 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
23 studies in Pneumonia by Pfizer: 3 open now, 3 under way, 2 of them phase 3. Of 16 finished, 7 (44%) have results posted.
Among the 23 studies in Pneumonia by Pfizer, this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is one of 5 that started in 2003, is one of 9 in phase 3, and was the 5th registered.
Pfizer’s Pneumonia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing azithromycin in Pneumonia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 23 in Pneumonia:
This tab as a report to print or save as PDF → With an account.
The study was performed to confirm that a single, 2.0 g oral dose of azithromycin sustained release (SR) at least as effective as 7 days of clarithromycin extended release (ER), 1.0 g by mouth once daily, when used to treat adults with mild to moderate community acquired pneumonia (CAP), and that both treatments were safe.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Outpatients with a diagnosis of pneumonia, as demonstrated by a productive cough and at least 2 of the following signs and symptoms: rales and/or evidence of pulmonary consolidation; dyspnea or tachypnea; elevated body temperature; or elevated total peripheral white blood cell count (WBC >10,000/mm3) or greater than 15% immature neutrophils were included. Patients were to have a chest radiograph demonstrating evidence of a new infiltrate or consolidation, and a Modified Fine Risk score of ≤ 70 (Fine Class I and II).
Exclusion Criteria:
Patients who were treated with any systemic antibiotic of greater than 1 dose or 1 combination dose (such as cephalosporin and macrolide) within the previous 7 days, or the likelihood of receiving other systemic antibiotics during participation in the study; were hospitalized in the previous 14 days or had an infection acquired in the hospital, and who were residents of a long-term care facility were excluded.
Drug: clarithromycin extended release (ER)
Drug: azithromycin SR
7 days of clarithromycin extended release (ER), 1.0 g by mouth once daily
Single, 2.0 g oral dose of azithromycin sustained release (SR) by mouth once daily
sponsor assessment of clinical response (clinical cure rate) in the Clinical Per Protocol population
Time frame: Test of Cure (TOC) visit (Day 14-21)
bacteriologic response (eradication rate) in the Bacteriological Per Protocol population
Time frame: TOC visit
investigator assessment of clinical response in the Clinical Per Protocol population
Time frame: TOC visit
sponsor assessment of clinical response by baseline pathogen
Time frame: End of Treatment (EOT) visit (Day 8-11) and TOC visit
sponsor assessment of clinical response in the non-primary population
Time frame: EOT visit and TOC visit
sponsor assessment of clinical responses in the Clinical Per Protocol population
Time frame: EOT visit and Long-Term Follow-Up (LTFU) visit (Day 28-35)
susceptibilities of baseline pathogens
Time frame: Study endpoint
adverse events
Time frame: Continuous
vital signs
Time frame: Baseline, On-Treatment (OT) visit (Day 3-5), and TOC visit
physical examination
Time frame: Baseline
clinical laboratory assessments (blood chemistry and hematology)
Time frame: Baseline and TOC visit
The record gives a start of Jan 2003 and a completion of Mar 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Clarithromycin · Azithromycin